Vivani Medical Eyes $3.50 Target, Validated by Novo Nordisk Deal

H.C. Wainwright reiterated a Buy rating for Vivani Medical, Inc. on July 10, 2026.

The firm maintained a $3.50 price target for the company.

This action follows an agreement with Novo Nordisk to evaluate NPM-139, an implant for long-term semaglutide delivery.

Analysts view the partnership as strong external validation for Vivani’s NanoPortal technology.

Successful Phase 1 trial results for NPM-139 may lead to a more substantial collaboration with the pharmaceutical giant.

Vivani's stock maintains positive momentum following a significant surge over the past week.